32 results on '"Manfrini, Marianna"'
Search Results
2. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
3. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
4. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
5. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
6. Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes
7. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
8. Recurrent disability progression endpoints in multiple sclerosis clinical trials
9. 020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years
10. 031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years
11. sj-docx-1-msj-10.1177_13524585221125382 – Supplemental material for Recurrent disability progression endpoints in multiple sclerosis clinical trials
12. Recurrent disability progression endpoints in multiple sclerosis clinical trials.
13. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma
14. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
15. Long-Term Reduction of Relapse Rate and Confirmed Disability Progression After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
16. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
17. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
18. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
19. Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847)
20. Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420)
21. Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807)
22. Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290)
23. Effect of Ocrelizumab on Thalamic Atrophy in Patients with Relapsing and Primary Progressive Multiple Sclerosis (1286)
24. Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091)
25. 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE)
26. Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366)
27. Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002)
28. Evaluation of cerebral hemodynamic in patients with subarachnoid hemorrhage: the role of perfusion computed tomography
29. Embolizzazione piu' radiochirurgia stereotassica con Gamma Knife nel trattamento delle malformazioni artero-venose cerebrali 'high grade'
30. Il ruolo della Gamma Knife nelle malformazioni artero-venose cerebrali nei pazienti pediatrici e adolescenti
31. Shorter Infusion Time of Ocrelizumab: Primary Results from the ENSEMBLE PLUS Study in Patients with Relapsing-Remitting Multiple Sclerosis.
32. Recurrent disability progression endpoints in multiple sclerosis clinical trials.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.